Johnson & Johnson

170.20-0.9100-0.53%Vol 4.61M1Y Perf -1.16%
Aug 8th, 2022 16:00 DELAYED
BID170.00 ASK170.90
Open171.30 Previous Close171.11
Pre-Market- After-Market170.79
 - -  0.59 0.35%
Target Price
186.33 
Analyst Rating
Moderate Buy 2.06
Potential %
9.48 
Finscreener Ranking
     39.18
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★     45.96
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★     53.23
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★★+     43.34
Price Range Ratio 52W %
46.75 
Earnings Rating
Sell
Market Cap447.49B 
Earnings Date
19th Jul 2022
Alpha0.00 Standard Deviation0.05
Beta0.63 

Today's Price Range

169.44171.48

52W Range

155.72186.69

5 Year PE Ratio Range

18.70310.40

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-1.57%
1 Month
-4.53%
3 Months
-4.02%
6 Months
-0.75%
1 Year
-1.16%
3 Years
28.90%
5 Years
27.75%
10 Years
176.52%

TickerPriceChg.Chg.%
JNJ170.20-0.9100-0.53
AAPL164.87-0.4800-0.29
GOOG118.14-0.0800-0.07
MSFT280.32-2.5900-0.92
XOM88.950.50000.57
WFC43.19-0.5700-1.30
FB196.640.99000.51
GE75.180.82001.10
JPM114.35-1.4100-1.22
 
ProfitabilityValueIndustryS&P 500US Markets
68.00
22.50
30.10
18.60
18.87
RevenueValueIndustryS&P 500US Markets
71.57B
27.20
4.58
4.50
DividendsValueIndustryS&P 500US Markets
2.59
4.52
4.92
5.56
Payout ratio61.00
Earnings HistoryEstimateReportedSurprise %
Q02 20222.572.590.78
Q01 20222.602.672.69
Q04 20212.122.130.47
Q03 20212.372.609.70
Q02 20212.282.488.77
Q01 20212.312.5912.12
Q04 20201.811.862.76
Q03 20201.992.2010.55
Earnings Per EndEstimateRevision %Trend
9/2022 QR2.56-1.92Negative
12/2022 QR2.21-6.36Negative
12/2022 FY10.05-1.47Negative
12/2023 FY10.53-2.05Negative
Next Report Date-
Estimated EPS Next Report2.57
Estimates Count7
EPS Growth Next 5 Years %5.20
Volume Overview
Volume4.61M
Shares Outstanding2.63M
Shares Float2.63B
Trades Count71.47K
Dollar Volume785.95M
Avg. Volume5.76M
Avg. Weekly Volume5.29M
Avg. Monthly Volume5.51M
Avg. Quarterly Volume6.47M

Johnson & Johnson (NYSE: JNJ) stock closed at 170.2 per share at the end of the most recent trading day (a -0.53% change compared to the prior day closing price) with a volume of 4.61M shares and market capitalization of 447.49B. Is a component of S&P 500, Dow Jones 30, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 136400 people. Johnson & Johnson CEO is Alex Gorsky.

The one-year performance of Johnson & Johnson stock is -1.16%, while year-to-date (YTD) performance is -0.51%. JNJ stock has a five-year performance of 27.75%. Its 52-week range is between 155.72 and 186.69, which gives JNJ stock a 52-week price range ratio of 46.75%

Johnson & Johnson currently has a PE ratio of 24.00, a price-to-book (PB) ratio of 6.28, a price-to-sale (PS) ratio of 6.41, a price to cashflow ratio of 20.40, a PEG ratio of 2.32, a ROA of 11.18%, a ROC of 19.19% and a ROE of 27.93%. The company’s profit margin is 18.87%, its EBITDA margin is 30.10%, and its revenue ttm is $71.57 Billion , which makes it $27.20 revenue per share.

Of the last four earnings reports from Johnson & Johnson, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.57 for the next earnings report. Johnson & Johnson’s next earnings report date is -.

The consensus rating of Wall Street analysts for Johnson & Johnson is Moderate Buy (2.06), with a target price of $186.33, which is +9.48% compared to the current price. The earnings rating for Johnson & Johnson stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Johnson & Johnson has a dividend yield of 2.59% with a dividend per share of $4.52 and a payout ratio of 61.00%.

Johnson & Johnson has a Sell technical analysis rating based on Technical Indicators (ADX : 9.82, ATR14 : 2.70, CCI20 : -128.81, Chaikin Money Flow : -0.01, MACD : -1.03, Money Flow Index : 43.32, ROC : 0.23, RSI : 48.51, STOCH (14,3) : 19.31, STOCH RSI : 0.00, UO : 47.00, Williams %R : -80.69), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Johnson & Johnson in the last 12-months were: Alex Gorsky (Option Excercise at a value of $30 325 274), Ashley McEvoy (Option Excercise at a value of $0), Jennifer L. Taubert (Option Excercise at a value of $0), Joaquin Duato (Option Excercise at a value of $11 037 462), Joseph J. Wolk (Option Excercise at a value of $0), Kathryn E. Wengel (Option Excercise at a value of $2 901 600), Kathryn E. Wengel (Sold 40 000 shares of value $6 920 039 ), Mathai Mammen (Option Excercise at a value of $0), Michael H. Ullmann (Option Excercise at a value of $0), Peter M. Fasolo (Option Excercise at a value of $0), Robert J. Decker (Option Excercise at a value of $1 339 234), Robert J. Decker (Sold 18 462 shares of value $3 216 740 ), Thibaut Mongon (Option Excercise at a value of $3 099 895), Thibaut Mongon (Sold 34 453 shares of value $6 072 408 ), Vanessa Broadhurst (Option Excercise at a value of $0), William Hait (Option Excercise at a value of $2 685 977), William Hait (Sold 29 599 shares of value $5 433 696 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (43.75 %)
6 (46.15 %)
5 (41.67 %)
Moderate Buy
1 (6.25 %)
1 (7.69 %)
1 (8.33 %)
Hold
8 (50.00 %)
6 (46.15 %)
6 (50.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
2.06
Moderate Buy
2.00
Moderate Buy
2.08

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total sales are generated in the United States.

CEO: Alex Gorsky

Telephone: +1 732 524-0400

Address: One Johnson and Johnson Plaza, New Brunswick 08933, NJ, US

Number of employees: 136 400

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

54%46%

Bearish Bullish

57%43%

Bearish Bullish

53%47%

TipRanks News for JNJ

Wed, 20 Jul 2022 12:43 GMT Johnson & Johnson (JNJ) Receives a Hold from Atlantic Equities

- TipRanks. All rights reserved.

Fri, 17 Jun 2022 03:47 GMT Why Johnson & Johnson Stock is Attractive Now

- TipRanks. All rights reserved.

Thu, 21 Apr 2022 03:15 GMT Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and AbbVie (ABBV)

- TipRanks. All rights reserved.

Thu, 21 Apr 2022 03:05 GMT Analysts Offer Insights on Healthcare Companies: Johnson & Johnson (JNJ) and Moderna (MRNA)

- TipRanks. All rights reserved.

Fri, 15 Apr 2022 06:11 GMT All Eyes on Johnson & Johnson as it Reports Q1 Earnings

- TipRanks. All rights reserved.

Wed, 02 Mar 2022 06:03 GMT Making Sense of Johnson & Johnsons Newly Added Risk Factors

- TipRanks. All rights reserved.

Tue, 18 Jan 2022 05:26 GMT Johnson & Johnson Settles Opioid Case with New Mexico

- TipRanks. All rights reserved.

Wed, 05 Jan 2022 16:30 GMT Johnson & Johnson: Concerning Growth, but Reliable Dividends

- TipRanks. All rights reserved.

News

Stocktwits